Englewood Cliffs, NJ, April 22, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that its Board of Directors has unanimously voted to uplist to the NASDAQ. Eric Weisblum, CEO, stated “Silo Pharma is proud to announce that we intend to begin the application process to list on…


Previous articleAion Therapeutic’s Proprietary Mushroom Preparations Shown Effective in Killing Breast Cancer Cells
Next articleChampignon Brands Announces Revocation of Cease Trade Orders